Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX

Molecular Pharmaceutics

Volumn 13, Issue 11, 2016, Pages 3676-3687

  Garousi, Javad ^a   Honarvar, Hadis ^a   Andersson, Ken G ^b   Mitran, Bogdan ^a   Orlova, Anna ^a   Buijs, Jos ^a,c   Löfblom, John ^b   Frejd, Fredrik Y ^a,d   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c Ridgeview Instruments AB   (Sweden)

^d Affibody AB   (Sweden)

Author keywords

affibody molecule; CAIX; imaging; radionuclide

Indexed keywords

CARBONATE DEHYDRATASE IX; EPITOPE; HE 3 AFFINITY MOLECULE ZCAIX 1 I 125; HE 3 AFFINITY MOLECULE ZCAIX 1 TC 99; HE 3 AFFINITY MOLECULE ZCAIX 2 I 125; HE 3 AFFINITY MOLECULE ZCAIX 2 TC 99; HE 3 AFFINITY MOLECULE ZCAIX 3 I 125; HE 3 AFFINITY MOLECULE ZCAIX 3 TC 99; HE 3 AFFINITY MOLECULE ZCAIX 4 I 125; HE 3 AFFINITY MOLECULE ZCAIX 4 TC 99; MOLECULAR SCAFFOLD; TRACER; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BLOOD; BONE; COLON; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DUODENUM; FEMALE; GASTROINTESTINAL TRACT; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; KIDNEY CARCINOMA; LIVER; LUNG; MOLECULAR IMAGING; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; STOMACH; ANIMAL; BAGG ALBINO MOUSE; DIAGNOSTIC IMAGING; HUMAN; KIDNEY TUMOR; METABOLISM; RENAL CELL CARCINOMA; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARBONIC ANHYDRASE IX; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; HETEROGRAFTS; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; RADIOPHARMACEUTICALS;

EID: 84994536143     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b00502     Document Type: Article

References (58)

1. Roskoski, R., Jr. The ErbB/HER family of protein-tyrosine kinases and cancer Pharmacol. Res. 2014, 79, 34-74 10.1016/j.phrs.2013.11.002
2. Chatalic, K. L.; Kwekkeboom, D. J.; de Jong, M. Radiopeptides for Imaging and Therapy: A Radiant Future J. Nucl. Med. 2015, 56, 1809-12 10.2967/jnumed.115.161158
3. Potter, C. P.; Harris, A. L. Diagnostic, prognostic and therapeutic implications of in cancer Br. J. Cancer 2003, 89, 2-7 10.1038/sj.bjc.6600936
4. McDonald, P. C.; Winum, J. Y.; Supuran, C. T.; Dedhar, S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics Oncotarget. 2012, 3, 84-97 10.18632/oncotarget.422
5. Tafreshi, N. K.; Lloyd, M. C.; Bui, M. M.; Gillies, R. J.; Morse, D. L. Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases Subcell. Biochem. 2014, 75, 221-54 10.1007/978-94-007-7359-2-12
6. De Simone, G.; Supuran, C. T. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target Biochim. Biophys. Acta, Proteins Proteomics 2010, 1804, 404-9 10.1016/j.bbapap.2009.07.027
7. Alterio, V.; Hilvo, M.; Di Fiore, A.; Supuran, C. T.; Pan, P.; Parkkila, S.; Scaloni, A.; Pastorek, J.; Pastorekova, S.; Pedone, C.; Scozzafava, A.; Monti, S. M.; De Simone, G. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 16233-8 10.1073/pnas.0908301106
8. Saarnio, J.; Parkkila, S.; Parkkila, A. K.; Waheed, A.; Casey, M. C.; Zhou, X. Y.; Pastorekova, S.; Pastorek, J.; Karttunen, T.; Haukipuro, K.; Kairaluoma, M. I.; Sly, W. S. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity J. Histochem. Cytochem. 1998, 46, 497-504 10.1177/002215549804600409
9. Pastorek, J.; Pastorekova, S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use Semin. Cancer Biol. 2015, 31, 52-64 10.1016/j.semcancer.2014.08.002
10. Wiesener, M. S.; Münchenhagen, P. M.; Berger, I.; Morgan, N. V.; Roigas, J.; Schwiertz, A.; Jürgensen, J. S.; Gruber, G.; Maxwell, P. H.; Löning, S. A.; Frei, U.; Maher, E. R.; Gröne, H. J.; Eckardt, K. U. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas Cancer Res. 2001, 61, 5215-22
11. Stillebroer, A. B.; Mulders, P. F.; Boerman, O. C.; Oyen, W. J.; Oosterwijk, E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy Eur. Urol. 2010, 58, 75-83 10.1016/j.eururo.2010.03.015
12. Gieling, R. G.; Parker, C. A.; De Costa, L. A.; Robertson, N.; Harris, A. L.; Stratford, I. J.; Williams, K. J. Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro J. Enzyme Inhib. Med. Chem. 2013, 28, 360-9 10.3109/14756366.2012.736979
13. Generali, D.; Berruti, A.; Brizzi, M. P.; Campo, L.; Bonardi, S.; Wigfield, S.; Bersiga, A.; Allevi, G.; Milani, M.; Aguggini, S.; Gandolfi, V.; Dogliotti, L.; Bottini, A.; Harris, A. L.; Fox, S. B. Hypoxia-inducible factor-1{alpha} expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer Clin. Cancer Res. 2006, 12, 4562-4568 10.1158/1078-0432.CCR-05-2690
14. Generali, D.; Fox, S. B.; Berruti, A.; Brizzi, M. P.; Campo, L.; Bonardi, S.; Wigfield, S. M.; Bruzzi, P.; Bersiga, A.; Allevi, G.; Milani, M.; Aguggini, S.; Dogliotti, L.; Bottini, A.; Harris, A. L. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer Endocr.-Relat. Cancer 2006, 13, 921-930 10.1677/erc.1.01216
15. Span, P. N.; Bussink, J.; Manders, P.; Beex, L. V.; Sweep, C. G. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome Br. J. Cancer 2003, 89, 271-27 10.1038/sj.bjc.6601122
16. Winum, J. Y.; Rami, M.; Scozzafava, A.; Montero, J. L.; Supuran, C. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents Med. Res. Rev. 2008, 28, 445-63 10.1002/med.20112
17. Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators Nat. Rev. Drug Discovery 2008, 7, 168-81 10.1038/nrd2467
18. Petrul, H. M.; Schatz, C. A.; Kopitz, C. C.; Adnane, L.; McCabe, T. J.; Trail, P.; Ha, S.; Chang, Y. S.; Voznesensky, A.; Ranges, G.; Tamburini, P. P. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9 Mol. Cancer Ther. 2012, 11, 340-9 10.1158/1535-7163.MCT-11-0523
19. Pettersen, E. O.; Ebbesen, P.; Gieling, R. G.; Williams, K. J.; Dubois, L.; Lambin, P.; Ward, C.; Meehan, J.; Kunkler, I. H.; Langdon, S. P.; Ree, A. H.; Flatmark, K.; Lyng, H.; Calzada, M. J.; Peso, L. D.; Landazuri, M. O.; Görlach, A.; Flamm, H.; Kieninger, J.; Urban, G.; Weltin, A.; Singleton, D. C.; Haider, S.; Buffa, F. M.; Harris, A. L.; Scozzafava, A.; Supuran, C. T.; Moser, I.; Jobst, G.; Busk, M.; Toustrup, K.; Overgaard, J.; Alsner, J.; Pouyssegur, J.; Chiche, J.; Mazure, N.; Marchiq, I.; Parks, S.; Ahmed, A.; Ashcroft, M.; Pastorekova, S.; Cao, Y.; Rouschop, K. M.; Wouters, B. G.; Koritzinsky, M.; Mujcic, H.; Cojocari, D. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium J. Enzyme Inhib. Med. Chem. 2015, 30, 689-721 10.3109/14756366.2014.966704
20. Loncaster, J. A.; Harris, A. L.; Davidson, S. E.; Logue, J. P.; Hunter, R. D.; Wycoff, C. C.; Pastorek, J.; Ratcliffe, P. J.; Stratford, I. J.; West, C. M. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix Cancer Res. 2001, 61, 6394-9
21. Beasley, N. J.; Wykoff, C. C.; Watson, P. H.; Leek, R.; Turley, H.; Gatter, K.; Pastorek, J.; Cox, G. J.; Ratcliffe, P.; Harris, A. L. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density Cancer. Res. 2001, 61, 5262-7
22. Ivanov, S.; Liao, S. Y.; Ivanova, A.; Danilkovitch-Miagkova, A.; Tarasova, N.; Weirich, G.; Merrill, M. J.; Proescholdt, M. A.; Oldfield, E. H.; Lee, J.; Zavada, J.; Waheed, A.; Sly, W.; Lerman, M. I.; Stanbridge, E. J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer Am. J. Pathol. 2001, 158, 905-19 10.1016/S0002-9440(10)64038-2
23. Vordermark, D.; Brown, J. M. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther. Onkol. 2003, 179, 801-11 10.1007/s00066-003-1150-9
24. Lo Dico, A.; Martelli, C.; Valtorta, S.; Raccagni, I.; Diceglie, C.; Belloli, S.; Gianelli, U.; Vaira, V.; Politi, L. S.; Bosari, S.; Lucignani, G.; Moresco, R. M.; Ottobrini, L. Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 1093-105 10.1007/s00259-015-3040-7
25. Schrijvers, M. L.; van der Laan, B. F.; de Bock, G. H.; Pattje, W. J.; Mastik, M. F.; Menkema, L.; Langendijk, J. A.; Kluin, P. M.; Schuuring, E.; van der Wal, J. E. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy Int. J. Radiat. Oncol., Biol., Phys. 2008, 72, 161-9 10.1016/j.ijrobp.2008.05.025
26. Kang, D. E.; White, R. L., Jr.; Zuger, J. H.; Sasser, H. C.; Teigland, C. M. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma J. Urol. 2004, 171, 1806-9 10.1097/01.ju.0000120241.50061.e4
27. Povoski, S. P.; Hall, N. C.; Murrey, D. A., Jr.; Sharp, D. S.; Hitchcock, C. L.; Mojzisik, C. M.; Bahnson, E. E.; Knopp, M. V.; Martin, E. W., Jr.; Bahnson, R. R. Multimodal imaging and detection strategy with 124 I-Labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma Surg. Innov. 2013, 20, 59-69 10.1177/1553350612438416
28. Hoeben, B. A.; Kaanders, J. H.; Franssen, G. M.; Troost, E. G.; Rijken, P. F.; Oosterwijk, E. et al. PET of hypoxia with 89Zr-labeled cG250-F(ab′)2 in head and neck tumors J. Nucl. Med. 2010, 51, 1076-83 10.2967/jnumed.109.073189
29. Ahlskog, J. K.; Schliemann, C.; MaÌŠrlind, J.; Qureshi, U.; Ammar, A.; Pedley, R. B.; Neri, D. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours Br. J. Cancer 2009, 18 (101) 645-57 10.1038/sj.bjc.6605200
30. Lau, J.; Pan, J.; Zhang, Z.; Hundal-Jabal, N.; Liu, Z.; Bénard, F.; Lin, K. S. Synthesis and evaluation of (18)F-labeled tertiary benzenesulfonamides for imaging carbonic anhydrase IX expression in tumours with positron emission tomography Bioorg. Med. Chem. Lett. 2014, 24, 3064-8 10.1016/j.bmcl.2014.05.021
31. Stillebroer, A. B.; Franssen, G. M.; Mulders, P. F.; Oyen, W. J.; van Dongen, G. A.; Laverman, P.; Oosterwijk, E.; Boerman, O. C. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice Cancer Biother.Radiopharm. 2013, 28, 510-5 10.1089/cbr.2013.1487
32. Miao, Z.; Levi, J.; Cheng, Z. Protein scaffold-based molecular probes for cancer molecular imaging Amino Acids 2011, 41, 1037-47 10.1007/s00726-010-0503-9
33. Stern, L. A.; Case, B. A.; Hackel, B. J. Alternative Non-Antibody Protein Scaffolds for Molecular Imaging of Cancer Curr. Opin. Chem. Eng. 2013, 2, 425-432 10.1016/j.coche.2013.08.009
34. Grönwall, C.; StaÌŠhl, S. Engineered affinity proteins - generation and applications J. Biotechnol. 2009, 25 (140) 254-69 10.1016/j.jbiotec.2009.01.014
35. Nygren, P. A. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold FEBS J. 2008, 275, 2668-76 10.1111/j.1742-4658.2008.06438.x
36. Löfblom, J.; Feldwisch, J.; Tolmachev, V.; Carlsson, J.; StaÌŠhl, S.; Frejd, F. Y. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications FEBS Lett. 2010, 584, 2670-80 10.1016/j.febslet.2010.04.014
37. Orlova, A.; Magnusson, M.; Eriksson, T. L.; Nilsson, M.; Larsson, B.; Höidén-Guthenberg, I.; Widström, C.; Carlsson, J.; Tolmachev, V.; StaÌŠhl, S.; Nilsson, F. Y. Tumor imaging using a picomolar affinity HER2 binding affibody molecule Cancer Res. 2006, 66, 4339-48 10.1158/0008-5472.CAN-05-3521
38. Garousi, J.; Andersson, K. G.; Mitran, B.; Pichl, M. L.; StaÌŠhl, S.; Orlova, A.; Löfblom, J.; Tolmachev, V. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules Int. J. Oncol. 2016, 48, 1325-32 10.3892/ijo.2016.3369
39. Mitran, B.; Altai, M.; Hofström, C.; Honarvar, H.; Sandström, M.; Orlova, A.; Tolmachev, V.; Gräslund, T. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression Amino Acids 2015, 47, 303-15 10.1007/s00726-014-1859-z
40. Rosestedt, M.; Andersson, K. G.; Mitran, B.; Tolmachev, V.; Löfblom, J.; Orlova, A.; StaÌŠhl, S. Affibody-mediated PET imaging of HER3 expression in malignant tumours Sci. Rep. 2015, 5, 15226 10.1038/srep15226
41. Strand, J.; Varasteh, Z.; Eriksson, O.; Abrahmsen, L.; Orlova, A.; Tolmachev, V. Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo Mol. Pharmaceutics 2014, 11, 3957-64 10.1021/mp500284t
42. Sörensen, J.; Sandberg, D.; Sandström, M.; Wennborg, A.; Feldwisch, J.; Tolmachev, V.; Åström, G.; Lubberink, M.; Garske-Román, U.; Carlsson, J.; Lindman, H. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule J. Nucl. Med. 2014, 55, 730-5 10.2967/jnumed.113.131243
43. Sörensen, J.; Velikyan, I.; Sandberg, D.; Wennborg, A.; Feldwisch, J.; Tolmachev, V.; Orlova, A.; Sandström, M.; Lubberink, M.; Olofsson, H.; Carlsson, J.; Lindman, H. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT Theranostics 2016, 6, 262-71 10.7150/thno.13502
44. Honarvar, H.; Garousi, J.; Gunneriusson, E.; Höidén-Guthenberg, I.; Altai, M.; Widström, C.; Tolmachev, V.; Frejd, F. Y. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule Int. J. Oncol. 2015, 46, 513-20 10.3892/ijo.2014.2782
45. Tolmachev, V.; Tran, T. A.; Rosik, D.; Sjöberg, A.; Abrahmsén, L.; Orlova, A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition J. Nucl. Med. 2012, 53, 953-60 10.2967/jnumed.111.101527
46. Andersson, K. G.; Rosestedt, M.; Varasteh, Z.; Malm, M.; Sandström, M.; Tolmachev, V.; Löfblom, J.; StaÌŠhl, S.; Orlova, A. Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors Oncol. Rep. 2015, 34, 1042-8 10.3892/or.2015.4046
47. Orlova, A.; WaÌŠllberg, H.; Stone-Elander, S.; Tolmachev, V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model J. Nucl. Med. 2009, 50, 417-25 10.2967/jnumed.108.057919
48. Waibel, R.; Alberto, R.; Willuda, J.; Finnern, R.; Schibli, R.; Stichelberger, A.; Egli, A.; Abram, U.; Mach, J. P.; Plückthun, A.; Schubiger, P. A. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex Nat. Biotechnol. 1999, 17, 897-901 10.1038/12890
49. WaÌŠllberg, H.; Orlova, A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers Cancer Biother.Radiopharm. 2008, 23, 435-442 10.1089/cbr.2008.0464
50. Tolmachev, V.; Orlova, A.; Andersson, K. Methods for radiolabelling of monoclonal antibodies Methods Mol. Biol. 2014, 1060, 309-30 10.1007/978-1-62703-586-6-16
51. Björkelund, H.; Gedda, L.; Barta, P.; Malmqvist, M.; Andersson, K. Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF PLoS One 2011, 6, e24739 10.1371/journal.pone.0024739
52. Orlova, A.; Hofström, C.; Strand, J.; Varasteh, Z.; Sandstrom, M.; Andersson, K.; Tolmachev, V.; Gräslund, T. [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 439-49 10.1007/s00259-012-2284-8
53. Tolmachev, V.; Orlova, A. Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets Curr. Med. Chem. 2010, 17, 2636-55 10.2174/092986710791859397
54. Wild, D.; Schmitt, J. S.; Ginj, M.; Mäcke, H. R.; Bernard, B. F.; Krenning, E.; De Jong, M.; Wenger, S.; Reubi, J. C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 1338-47 10.1007/s00259-003-1255-5
55. Schottelius, M.; Šimeček, J.; Hoffmann, F.; Willibald, M.; Schwaiger, M.; Wester, H. J. Twins in spirit-episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE EJNMMI Res. 2015, 5, 22 10.1186/s13550-015-0099-x
56. Kobayashi, H.; Kao, C. H.; Kreitman, R. J.; Le, N.; Kim, M. K.; Brechbiel, M. W.; Paik, C. H.; Pastan, I.; Carrasquillo, J. A. Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin J. Nucl. Med. 2000, 41, 755-62
57. Rosik, D.; Orlova, A.; Malmberg, J.; Altai, M.; Varasteh, Z.; Sandström, M.; Karlström, A. E.; Tolmachev, V. Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 693-702 10.1007/s00259-011-2016-5
58. Altai, M.; Perols, A.; Karlström, A. E.; Sandström, M.; Boschetti, F.; Orlova, A.; Tolmachev, V. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA Nucl. Med. Biol. 2012, 39, 518-29 10.1016/j.nucmedbio.2011.10.013